证券代码： 002626 证券简称：金达威 编号：20140903 厦门金达威集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------|--------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中航证券有限公司 沈文文 | | | 人员姓名 | 上海互码投资管理事务所 陈凌 | | | | | 中国银河证券股份有限公司 谭勇、郭思捷、杨岚 | | | | | | 时间 | 2014 年 09 月 03 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人 员姓名 | 洪彦、丁雪萍、祝亚 | | | 投资者关系活动 | 一、调研方式：座谈 | | | ...

证券代码： 002626 证券简称：金达威 编号：20150715 厦门金达威集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 浙商证券股份有限公司研究所行业公司部 方叶 | | 人员姓名 | | | | | | | | 时间 | 2015 年 07 月 15 | 日 | | 地点 | 公司会议室 | | | 上市公司接待人 员姓名 | 洪彦 | | | 投资者关系活动 | 一、调研方式：座谈 | | | 主要内容介绍 | 二、主要内容： | | | | 1 、公司的战略规划 | | | ...

Group 1: Demographic Trends - China entered an aging society in 1999, being one of the earliest developing countries to do so [3] - By 2023, the elderly population in China is projected to reach 270 million, equal to the population of children aged 0-14 [3] - By 2050, the elderly population is expected to exceed 400 million, with an aging level approaching 30% [3] Group 2: Healthcare Spending - In 2014, the per capita disposable income in China was 20,167 yuan, comparable to the U.S. level in the early 1980s [3] - Healthcare spending as a percentage of personal consumption has been continuously increasing in the U.S. since 1980 [3] Group 3: Market Opportunities - The health supplement industry in China is expected to grow rapidly due to the increasing elderly population and rising living standards [4] - Vitatech, a leading health supplement manufacturer in North America, has a production capacity exceeding 600 million kg of powders, 1.8 billion tablets, and 1.2 billion hard capsules annually [4][5] Group 4: Business Strategy - The company plans to leverage Vitatech's existing production capacity to reduce costs and increase revenue post-acquisition [5] - The company aims to develop its own brands, Cinsulin and Body & Soul, while expanding its sales channels [5][6] Group 5: Sales Channels - Key sales channels for the company's products include its official online store, JD.com, a hotline for mail orders, and various offline pharmacies [6]

Group 1: Market Context and Demographics - China entered an aging society in 1999, being one of the earliest developing countries to do so, with the elderly population accounting for one-fifth of the global total [2] - By 2023, the elderly population in China is projected to reach 270 million, equal to the number of children aged 0-14 [2] - By 2050, the elderly population is expected to exceed 400 million, with an aging level approaching 30% [2] Group 2: Health Care Spending Trends - Health care spending as a percentage of personal consumption has been on the rise in the U.S. since the 1980s, indicating a long-term trend [2] - In 2014, the per capita disposable income in China was 20,167 yuan, comparable to the U.S. level in the early 1980s [2] Group 3: Company Strategy and Product Development - The company focuses on health products due to the increasing elderly population and rising living standards, which present a growth opportunity for the health supplement industry [3] - The company has successfully transitioned its DRB products in China through cross-border e-commerce and established flagship stores on platforms like JD.com [3] - The company aims to leverage Vitatech's existing production capacity to reduce costs and increase revenue post-acquisition [5] Group 4: Sales Channels and Product Offerings - Coenzyme Q10, a key health supplement, is marketed through various channels including the company's official store, JD.com, and offline pharmacies [5] - Vitatech, acquired by the company, has the capacity to produce over 6 million kilograms of powder, 1.8 billion tablets, and 1.2 billion hard capsules annually [4]

Group 1: Strategic Transformation - The company is accelerating its strategic transformation towards globalization and product specialization, evidenced by recent acquisitions in the dietary supplement sector [1] - The acquisition of Doctor's Best Holdings, Inc. marks a successful expansion from raw material supply to end-product sales [2] - The recent acquisition of Vitatech Nutrition Sciences, Inc. enhances the company's health product production line, completing its supply chain from raw materials to sales [2] Group 2: Sales Plans and Channels - Doctor's Best brand products are primarily sold through cross-border e-commerce platforms and a flagship store on JD.com, aiming to enhance brand influence in both domestic and international markets [2] - The sales channels for the company's Coenzyme Q10 product include its official mall, JD.com, and various pharmacies, with ongoing efforts to diversify sales channels [3] Group 3: Future Development and Profitability - The company plans to utilize existing production capacity from VitaBest to reduce production costs and increase revenue through synergy effects [3] - The decline in profits for 2015 is attributed to the continued low prices of Vitamin A products and increased costs from new product promotions [4]

证券代码： 002626 证券简称：金达威 编号：20141119 厦门金达威集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------|-------------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 摩根士丹利华鑫基金管理有限公司 缪东航 | | 人员姓名 | | | | 时间 | 2014 年 11 月 | 19 日 | | 地点 | 公司会议室 | | | 上市公司接待人 | 洪彦 丁雪萍 祝亚 | | | 员姓名 | | | | 投资者关系活动 | 一、调研方式：座谈 | | | 主要内容介绍 | 二、主要内容： | | | | 1、公司主要产品的产地 | | ...

Group 1: Company Expansion Plans - The company is advancing into the health supplement sector, enhancing its competitive position in the nutrition fortifier and feed additive industries while actively expanding downstream in the supply chain [2] - The company has launched Coenzyme Q10 soft capsules, primarily sold through the "Jindawi Mall" channel, which is currently in trial operation [3] - The acquisition of Doctor's Best Holdings, Inc. allows the company to quickly enter the U.S. health supplement market and expand its product line, with approximately 180 dietary supplements ranked highly on platforms like Amazon and iHerb [3] Group 2: Product Production and Raw Materials - Coenzyme Q10, DHA, and plant-based ARA are produced through microbial fermentation, with main raw materials including liquid sugar, β-violet ketone, and cholesterol [3] - The production technology for Coenzyme Q10 is self-developed and patented, with stable price fluctuations and a rapidly growing market demand [3] - The price trends for VA and VD3 are influenced by raw material costs, supply conditions, and market expectations [4] Group 3: Market Development and Competitive Advantage - The company's products have been included in the qualified supplier lists of major domestic dairy enterprises, indicating strong market potential [4] - The company plans to increase research and promotion efforts for DHA and ARA in various application fields, leveraging its competitive advantages in production technology [4]

Group 1: Strategic Transformation - The company is accelerating its strategic transformation towards global production and product specialization, as evidenced by recent developments [1] - The acquisition of dietary supplements company VITATECH will enhance the company's existing business and expand its health product production line to meet international standards [2] - The transaction aims to complete a full industrial chain layout from raw material supply to product manufacturing and terminal product sales, leveraging existing production capacity to reduce costs and improve profitability [2] Group 2: Product Sales Channels - Coenzyme Q10, a popular health supplement, is gaining traction in the global market due to its benefits in enhancing immunity and cardiovascular protection [2] - Major sales channels for the company's Coenzyme Q10 product include: 1) Official online store, 2) JD.com, 3) Hotline mail order, and 4) Offline channels that are gradually being established [2] - Existing retail partners include various pharmaceutical companies and pharmacies across different regions, indicating a growing distribution network [3]